TrialArthritis research & therapy2006

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

Ralf H Wittenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.